Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
383 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Thyroid Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 29, 21, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively. Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Thyroid Cancer - Overview 9 Thyroid Cancer - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 16 Products under Development by Universities/Institutes 21 Thyroid Cancer - Therapeutics Assessment 22 Assessment by Target 22 Assessment by Mechanism of Action 26 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Thyroid Cancer - Companies Involved in Therapeutics Development 34 AbbVie Inc 34 Advenchen Laboratories LLC 34 AstraZeneca Plc 35 Bayer AG 35 BeiGene Ltd 36 Biovista Inc 36 Blueprint Medicines Corp 37 Boehringer Ingelheim GmbH 37 Celgene Corp 38 Celldex Therapeutics Inc 38 Cytori Therapeutics Inc 39 Daiichi Sankyo Company Ltd 39 Ecrins Therapeutics SAS 40 Eisai Co Ltd 40 Ensol Biosciences Inc 41 F. Hoffmann-La Roche Ltd 41 Genelux Corp 42 Genmab A/S 42 GlaxoSmithKline Plc 43 Gradalis Inc 43 Hutchison MediPharma Ltd 44 Ignyta Inc 44 Immune Pharmaceuticals Inc 45 Immunomedics Inc 45 Johnson & Johnson 46 Loxo Oncology Inc 46 MacroGenics Inc 47 MaxiVAX SA 47 Merck & Co Inc 48 Merck KGaA 48 Millennium Pharmaceuticals Inc 49 Nerviano Medical Sciences Srl 49 Novartis AG 50 Ono Pharmaceutical Co Ltd 51 Pfizer Inc 52 Plexxikon Inc 53 Rodos BioTarget GmbH 53 Savoy Pharmaceuticals Inc 54 Synactix Pharmaceuticals Inc 54 Tarveda Therapeutics Inc 55 Vaccinex Inc 55 Vascular Biogenics Ltd 56 Thyroid Cancer - Drug Profiles 57 AL-3818 - Drug Profile 57 BGB-283 - Drug Profile 60 BGBA-317 - Drug Profile 63 BLU-667 - Drug Profile 65 BVA-501 - Drug Profile 66 BVA-701 - Drug Profile 67 CDX-3379 - Drug Profile 68 ceritinib - Drug Profile 72 Charis-1000 - Drug Profile 79 CLM-24 - Drug Profile 80 CLM-29 - Drug Profile 81 CLM-3 - Drug Profile 82 CLM-94 - Drug Profile 83 crizotinib - Drug Profile 84 crolibulin - Drug Profile 91 dabrafenib mesylate - Drug Profile 93 dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 98 docetaxel - Drug Profile 105 donafenib - Drug Profile 107 efatutazone - Drug Profile 108 enoblituzumab - Drug Profile 110 entrectinib - Drug Profile 113 ETD-5 - Drug Profile 120 everolimus - Drug Profile 121 FAZ-053 - Drug Profile 135 gemogenovatucel-T - Drug Profile 136 GI-6207 - Drug Profile 141 GLONC-2 - Drug Profile 143 GSK-2256098 - Drug Profile 144 HMPL-012 - Drug Profile 146 HuMax-AXL-ADC - Drug Profile 150 JB-002 - Drug Profile 151 larotrectinib - Drug Profile 152 lenvatinib mesylate - Drug Profile 157 LOXO-292 - Drug Profile 170 MGD-009 - Drug Profile 171 MVXONCO-1 - Drug Profile 173 nintedanib - Drug Profile 175 NMS-616 - Drug Profile 186 ofranergene obadenovec - Drug Profile 187 Oncoprev - Drug Profile 194 ONO-8430506 - Drug Profile 195 panobinostat - Drug Profile 196 pasireotide - Drug Profile 204 pazopanib hydrochloride - Drug Profile 208 PDR-001 - Drug Profile 217 pembrolizumab - Drug Profile 219 PEN-221 - Drug Profile 267 pexidartinib - Drug Profile 269 pimasertib hydrochloride + voxtalisib - Drug Profile 274 PLX-7486 - Drug Profile 276 PLX-8394 - Drug Profile 277 Recombinant Protein for Thyroid Cancer - Drug Profile 278 regorafenib - Drug Profile 279 rovalpituzumab tesirine - Drug Profile 291 RXDX-105 - Drug Profile 293 sacituzumab - Drug Profile 296 sapanisertib - Drug Profile 307 selumetinib sulfate - Drug Profile 310 Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 317 Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 318 Small Molecules to Inhibit ALK for Oncology - Drug Profile 319 Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile 320 sunitinib malate - Drug Profile 321 SYN-001 - Drug Profile 326 temsirolimus - Drug Profile 327 TF-2 - Drug Profile 330 tipifarnib - Drug Profile 333 TQB-3234 - Drug Profile 337 trametinib dimethyl sulfoxide - Drug Profile 338 UB-941 - Drug Profile 343 utomilumab - Drug Profile 344 vemurafenib - Drug Profile 347 VIMO-001 - Drug Profile 355 VX-15 - Drug Profile 356 Thyroid Cancer - Dormant Projects 361 Thyroid Cancer - Discontinued Products 363 Thyroid Cancer - Product Development Milestones 364 Featured News & Press Releases 364 Appendix 377 Methodology 377 Coverage 377 Secondary Research 377 Primary Research 377 Expert Panel Validation 377 Contact Us 377 Disclaimer 378
List of Tables
Number of Products under Development for Thyroid Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Thyroid Cancer - Pipeline by AbbVie Inc, H1 2017 Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 Thyroid Cancer - Pipeline by AstraZeneca Plc, H1 2017 Thyroid Cancer - Pipeline by Bayer AG, H1 2017 Thyroid Cancer - Pipeline by BeiGene Ltd, H1 2017 Thyroid Cancer - Pipeline by Biovista Inc, H1 2017 Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H1 2017 Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Thyroid Cancer - Pipeline by Celgene Corp, H1 2017 Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2017 Thyroid Cancer - Pipeline by Eisai Co Ltd, H1 2017 Thyroid Cancer - Pipeline by Ensol Biosciences Inc, H1 2017 Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Thyroid Cancer - Pipeline by Genelux Corp, H1 2017 Thyroid Cancer - Pipeline by Genmab A/S, H1 2017 Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 Thyroid Cancer - Pipeline by Gradalis Inc, H1 2017 Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2017 Thyroid Cancer - Pipeline by Ignyta Inc, H1 2017 Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Immunomedics Inc, H1 2017 Thyroid Cancer - Pipeline by Johnson & Johnson, H1 2017 Thyroid Cancer - Pipeline by Loxo Oncology Inc, H1 2017 Thyroid Cancer - Pipeline by MacroGenics Inc, H1 2017 Thyroid Cancer - Pipeline by MaxiVAX SA, H1 2017 Thyroid Cancer - Pipeline by Merck & Co Inc, H1 2017 Thyroid Cancer - Pipeline by Merck KGaA, H1 2017 Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017 Thyroid Cancer - Pipeline by Novartis AG, H1 2017 Thyroid Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Thyroid Cancer - Pipeline by Pfizer Inc, H1 2017 Thyroid Cancer - Pipeline by Plexxikon Inc, H1 2017 Thyroid Cancer - Pipeline by Rodos BioTarget GmbH, H1 2017 Thyroid Cancer - Pipeline by Savoy Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Synactix Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Vaccinex Inc, H1 2017 Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017 Thyroid Cancer - Dormant Projects, H1 2017 Thyroid Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017 Thyroid Cancer - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.